-

Butterfly Announces CEO Transition

BURLINGTON, Mass. & NEW YORK--(BUSINESS WIRE)--Butterfly Network, Inc. (NYSE: BFLY) (“Butterfly” the “Company”), a digital health company transforming care with handheld, whole-body ultrasound, announced that the Company and Todd Fruchterman, M.D., Ph.D. have mutually agreed that Dr. Fruchterman will leave his position as President and Chief Executive Officer and as a member of the Board of Directors. Dr. Fruchterman will partner with Butterfly’s leadership team through the end of the year to ensure a smooth transition.

“On behalf of the Board I want to thank Todd for his vision, passion and dedication to Butterfly during his tenure,” said Jonathan Rothberg, Founder and Chairman of the Board. “Todd has built a highly capable leadership team, who will function in the interim to ensure continuity while we conduct a search for a new chief executive who will continue the company’s growth.”

Dr. Rothberg will serve as Interim CEO during this time of transition and will work closely with Butterfly’s executive team to continue to drive the Company forward and ensure business continuity during the search for a permanent replacement.

About Butterfly Network, Inc.
Founded by Dr. Jonathan Rothberg in 2011 and listed on the New York Stock Exchange through a business combination with Longview Acquisition Corp., Butterfly created the world's first handheld, single probe whole-body ultrasound system using semiconductor technology, the Butterfly iQ+. Butterfly's mission is to democratize medical imaging and contribute to the aspiration of global health equity, making high-quality ultrasound affordable, easy-to-use, globally accessible, and intelligently connected, including for the 4.7 billion people around the world lacking access to ultrasound. Through its proprietary Ultrasound-on-Chip™ technology, Butterfly is paving the way for earlier detection and remote management of health conditions around the world. The Butterfly iQ+ can be purchased online today by healthcare practitioners in the United States, Australia, Austria, Belgium, Canada, Denmark, Finland, France, Germany, Ireland, Italy, the Netherlands, New Zealand, Norway, Poland, Portugal, Spain, Sweden, Switzerland, and the United Kingdom.

Butterfly iQ+ is a prescription device intended for trained healthcare professionals only.

Contacts

Investors
Heather Getz
hgetz@butterflynetinc.com

Butterfly Network, Inc.

NYSE:BFLY

Release Versions

Contacts

Investors
Heather Getz
hgetz@butterflynetinc.com

More News From Butterfly Network, Inc.

Butterfly Network to Participate at TD Cowen 46th Annual Health Care Conference on March 3, 2026

NEW YORK & BURLINGTON, Mass.--(BUSINESS WIRE)--Butterfly Network, Inc. (NYSE: BFLY) (“Butterfly”), a digital health company transforming care with semiconductor chip-based ultrasound devices, software and AI, today announced that it will participate at the TD Cowen 46th Annual Health Care Conference in Boston on March 3, 2026. Joseph DeVivo, President, Chief Executive Officer & Chairman; John Doherty, EVP, Chief Financial Officer; and Megan Carlson, SVP, Accounting & Finance – Chief Acc...

Butterfly Network Achieves GovRAMP and TX-RAMP Information Security Certifications

BURLINGTON, Mass. & NEW YORK--(BUSINESS WIRE)--Butterfly Network, Inc. (“Butterfly”, “the Company”) (NYSE: BFLY), a digital health company transforming care with semiconductor chip-based ultrasound devices, software and AI, today announced that its Butterfly iQ+/iQ3 and Compass AI™ ultrasound solution have achieved GovRAMP and TX-RAMP Authorizations. The certifications authorize the Company to sell cloud services to all state and local government agencies, including in the state of Texas. GovRA...

Butterfly Network to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

BURLINGTON, Mass. & NEW YORK--(BUSINESS WIRE)--Butterfly Network, Inc. (NYSE: BFLY) (“Butterfly”), a digital health company transforming care with portable, semiconductor-based ultrasound technology and intuitive software, announced that it will report fourth quarter and full year 2025 financial results on Thursday, February 26, 2026, at 8:00 am ET. Joseph DeVivo, President, Chief Executive Officer and Chairman of the Board, and John Doherty, Executive Vice President and Chief Financial Officer...
Back to Newsroom